医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Aptorum Group

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

バイオテクノロジーヘルスケア感染症腫瘍学臨床試験製薬　 TimeLine: Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

2023年03月27日

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology – a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology – a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

バイオテクノロジーヘルスケア感染症腫瘍学臨床試験製薬　 TimeLine: a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms Announces Publication of a Co-authored Paper on its PathsDx Aptorum Group Technology

2023年01月04日

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: Announces Completion of Aptorum Group Million Convertible Note due 2023

2022年12月16日

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

ヘルスケアヘルス一般感染症臨床試験製薬　 TimeLine: Aptorum Group its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma Receives FDA Orphan Drug Designation for

2022年01月20日

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers Aptorum Group

2022年01月10日

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: ALS-4 and SACT-1 Announces Completion of Phase Aptorum Group I Clinical Trials for Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

2022年01月10日

Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

2021年04月22日

Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in Celebration of IPO Closing

Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in Celebration of IPO Closing

ヘルスケア外科感染症腫瘍学臨床試験製薬　 TimeLine: Aptorum Group Celebration of IPO Closing to Ring the NASDAQ Stock Market Closing

2018年12月18日